• Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.


• Where is my product positioned vs. competitors in the treatment journey?

• What are physicians’ most frequent treatment sequences—who is

benefiting and how can I defend my assets share and position?

• What are the market-relevant treatment scenarios according to oncology


• Where are the untapped business opportunities that I can capitalize


• How can I optimize trial design and ensure a competitive edge for my

pipeline asset?


United States


Survey of ~100 U.S. physicians


Colorectal Cancer (US)

Multiple Myeloma (US)

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (US)

Non-Small-Cell Lung Cancer (US)

Ovarian Cancer (US)

Prostate Cancer (US)

Renal Cell Carcinoma (US)


  • Market-relevant treatment scenarios and subpopulations from oncology experts
  • Drug share and treatment rates mapped to treatment journey using physician survey data
  • Physicians’ most frequently selected treatment sequences
  • Access to expert oncology analysts for bespoke support


Treatment Sequencing provides disease-specific, sequential treatment

patterns in market-relevant treatment scenarios and drug share mapped to

treatment journey. The quantitative sequencing analysis illuminates drug

positioning through primary market research-based insights from physicians

and DRG oncology experts’ assumptions.

Table of contents

  • Detailed, Expanded Analysis: Treatment Sequencing (US)
    • Treatment Sequencing Renal Cell Carcinoma US June 2019

Author(s): Sudha Malhotra, Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.

Related Reports

Renal Cell Carcinoma | Landscape & Forecast | Disease Landscape & Forecast

Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor Opdivo in the recurrent renal cell carcinoma setting, comb...

View Details

Renal Cell Carcinoma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma ...

View Details

Renal Cell Carcinoma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalenc...

View Details

Renal Cell Carcinoma | Current Treatment | Detailed, Expanded Analysis (US)

Market O

View Details